Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition

MLA

Tom van den Ende, et al. “Longitudinal Immune Monitoring of Patients with Resectable Esophageal Adenocarcinoma Treated with Neoadjuvant PD-L1 Checkpoint Inhibition.” OncoImmunology, vol. 12, no. 1, Dec. 2023. EBSCOhost, https://doi.org/10.1080/2162402X.2023.2233403.

APA

Tom van den Ende, Aiarpi Ezdoglian, Lisanne M. Baas, Joyce Bakker, Sinéad M. Lougheed, Micaela Harrasser, Cynthia Waasdorp, Mark I. van Berge Henegouwen, Maarten C.C.M. Hulshof, Nadia Haj Mohammad, Richard van Hillegersberg, Stella Mook, Conny J. van der Laken, Nicole C.T. van Grieken, Sarah Derks, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven, & Tanja D. de Gruijl. (2023). Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition. OncoImmunology, 12(1). https://doi.org/10.1080/2162402X.2023.2233403

Chicago

Tom van den Ende, Aiarpi Ezdoglian, Lisanne M. Baas, Joyce Bakker, Sinéad M. Lougheed, Micaela Harrasser, Cynthia Waasdorp, et al. 2023. “Longitudinal Immune Monitoring of Patients with Resectable Esophageal Adenocarcinoma Treated with Neoadjuvant PD-L1 Checkpoint Inhibition.” OncoImmunology 12 (1). doi:10.1080/2162402X.2023.2233403.